The role of sleep in telogen effluvium and trichodynia: A commentary in the context of the current pandemic

Xerfan, Ellen M S; Andersen, Mônica Levy; Facina, Anamaria S; Tufik, Sérgio; Tomimori, Jane

doi:10.1111/jocd.13929

Cited by 6 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination of increased stress, frequent hair wash to avoid virus transmission, and sleep disorders can result in TR more or less being associated with hair loss. 32 Interestingly, in our sample, anosmia correlated with TR 1 /TE À both in the multivariate and univariate analyses, whereas dysgeusia correlated with TE 1 /TR 1 in the multivariate analysis. Overall, both anosmia and dysgeusia largely prevailed in TR 1 patients, possibly suggesting its neurogenic role in patients with this condition.…”

Section: Discussionmentioning

confidence: 48%

Trichodynia and telogen effluvium in COVID-19 patients: Results of an international expert opinion survey on diagnosis and management

Starace

Iorizzo²,

Sechi

et al. 2021

JAAD International

View full text Add to dashboard Cite

Background Cutaneous manifestations of COVID-19 may be useful disease markers and prognostic indicators. Recently, post-infectious telogen effluvium and trichodynia have also been reported. Objective To evaluate the presence of trichodynia and telogen effluvium in patients with COVID-19 and describe their characteristics in relation to other signs and symptoms of the disease. Methods Patients with a history of COVID-19 presenting to the clinics of a group of hair experts because of telogen effluvium and/or scalp symptoms, were questioned with regards about their hair signs and symptoms in relation to the severity of COVID-19 and associated symptoms. Results Data from 128 patients were collected. Telogen effluvium was observed in 66.3% of patients and trichodynia in 58.4%. Trichodynia was associated to telogen effluvium in 42.4% of cases and was associated to anosmia and ageusia in 66.1% and 44.1% of cases, respectively. In the majority of patients (62.5%), hair signs and symptoms started within the first month post-COVID-19 diagnosis and in 47.8% of patients after 12 weeks or more. Limitations Recruitment of patient in specialized hair clinics, lack of a control group, and lack of recording of patient comorbidities. Conclusion The severity of the post-viral telogen effluvium observed in patients with a history of COVID-19 infection is influenced by COVID-19 severity. We identified an early onset (<4 weeks) and a late onset (>12 weeks) telogen effluvium.

show abstract

Section: Discussionmentioning

confidence: 48%

Trichodynia and telogen effluvium in COVID-19 patients: Results of an international expert opinion survey on diagnosis and management

Starace

Iorizzo²,

Sechi

et al. 2021

JAAD International

View full text Add to dashboard Cite

show abstract

“…Trichodynia is a symptom of local paresthesia often associated with telogen effluvium, androgenetic alopecia, and alopecia areata [ 27 , 28 ]. It is a crucial dermatological marker of the severity of hair disease and the response to treatment [ 29 ].…”

Section: Discussionmentioning

confidence: 99%

Antinuclear Antibody Positivity in Patients With Hair Loss After COVID-19 Infection

Manav

Erdil

Aksu

2023

Dermatol Pract Concept

View full text Add to dashboard Cite

Introduction: Hair loss is one of the most common disorders after coronavirus disease 2019 (COVID-19) infection. This study aimed to investigate the relationship between COVID-19-related hair loss and antinuclear antibody (ANA) positivity and patterns. Methods: ANA positivity and patterns were analyzed in 30 female COVID-19 patients with hair loss complaints and compared in terms of the presence of autoimmunity between patients with and without COVID-19 exhibiting hair loss. Results: ANA positivity and cytoplasmic patterns were detected in 40% of the patients with COVID-19 infection and hair loss. Trichodynia and diffuse hair loss were observed in 63.3% and 53.3%, respectively. Conclusions: In patients with COVID-19-related hair loss, diffuse hair loss and ANA positivity may be related to the high antibody levels triggered by COVID-19 infection.

show abstract

“…It has been suggested that the painful sensation associated with trichodynia is related to the increased or dysregulated levels of SP. The underlying cause may be poor sleep because it is a source of stress, which can influence the regulation of SP (14).…”

Section: Etiopathogenesismentioning

confidence: 99%

Trichodynia: An Update on Definition, Etiopathogenesis, Diagnosis, and Treatment

El‐Hamd

Aboeldahab

2022

J Skin Stem Cell

View full text Add to dashboard Cite

: Trichodynia was elucidated as a distressing, painful sensation of the scalp hair and/or the skin of the scalp that becomes more vigorous when hairs are touched without an underlying cutaneous disease and is frequently associated with hair shedding. It was often more in women than men, directly correlating with hair loss. The etiology of trichodynia is not well-known, but it may be multifactorial. Several possible hypotheses can explain the etiopathogenesis of trichodynia, including enhanced expression of neuropeptide substance P with perifollicular inflammation, psychiatric diseases, and nutritional deficiencies. Currently, there is no specific and effective therapy for trichodynia. Various available treatments included L-cystine-containing oral preparation, topical corticosteroid, low-dose antidepressant, oral propranolol, and botulinum toxin injection. This review article highlights an update of the definition, etiopathogenesis, diagnosis, and treatment of trichodynia.

show abstract

The role of sleep in telogen effluvium and trichodynia: A commentary in the context of the current pandemic

Cited by 6 publications

References 16 publications

Trichodynia and telogen effluvium in COVID-19 patients: Results of an international expert opinion survey on diagnosis and management

Trichodynia and telogen effluvium in COVID-19 patients: Results of an international expert opinion survey on diagnosis and management

Antinuclear Antibody Positivity in Patients With Hair Loss After COVID-19 Infection

Trichodynia: An Update on Definition, Etiopathogenesis, Diagnosis, and Treatment

Contact Info

Product

Resources

About